Literature DB >> 11602082

Implications of recent heart failure trials for patients with hypertension.

P A Poole-Wilson1.   

Abstract

There are two major reasons why hypertension is an important risk factor for heart failure. The first is that an elevated blood pressure increases the wall stress in the left ventricle. The second is that hypertension, in a complex manner, contributes to the development of atheromatous vascular disease. Among the more common causes of heart failure are the sequelae of coronary heart disease. The treatment of hypertension modifies the progression to heart failure and the occurrence of coronary events. In patients who have heart failure, hypotension rather than hypertension is a predictor of a poor outcome, likely because low blood pressure is a consequence of damage to the myocardium. The clinical message is that hypertension should be treated aggressively. Where heart failure is a likely outcome, or where hypertension occurs in the presence of heart failure, there is a strong case for using drugs that have been shown to be beneficial in the treatment of both hypertension and heart failure.

Entities:  

Mesh:

Year:  2001        PMID: 11602082     DOI: 10.1007/s11886-001-0073-2

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  41 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population.

Authors:  T A McDonagh; C E Morrison; A Lawrence; I Ford; H Tunstall-Pedoe; J J McMurray; H J Dargie
Journal:  Lancet       Date:  1997-09-20       Impact factor: 79.321

4.  Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study.

Authors:  H Schirmer; P Lunde; K Rasmussen
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Survival of patients with a new diagnosis of heart failure: a population based study.

Authors:  M R Cowie; D A Wood; A J Coats; S G Thompson; V Suresh; P A Poole-Wilson; G C Sutton
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

7.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease.

Authors:  J K Ghali; Y Liao; R S Cooper
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

9.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

10.  Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.

Authors:  G Johnson; P Carson; G S Francis; J N Cohn
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.